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ABSTRACT
Title of Thesis:

Scheduling Effects of 5-(3,3-Dimethyl-1triazeno)imidazole-4-carboxamide (DTIC)
and 1,3-Bis-chloroethyl-1-nitrosourea
(BCNU) on Mouse Melanoma Cells B16CL4

Gracie V. Coffey,

Master of Science, Environmental Engineering, Designated Degree, (Toxicology
Option), 1985

Thesis directed by: Professor Helene Z. Hill and
Professor Richard Trattner
DTIC and BCNU have been demonstrated to have enhanced
chemotherapeutic effects in mice bearing B16 mouse
melanoma cells. The order of administration seems to be
important in maintaining optimum effects. This was shown is
a study by Hill et al. (unpublished).
In the present study, mouse melanoma cells, B16CL4, were
treated with either DTIC or BCNU. The drug was allowed to
remain on the cells for 2, 3, or 4 days. The drug-containing
media were then removed, the cells were washed and fresh
medium was added. The cells were incubated in an atmosphere
of 5% CO2 and 95% air at 37 °C. In combination experiments,
dishes of B16CL4 cells were treated with DTIC on day 0. BCNU
was then added on days 0, 1, or 2 of exposure. At the end of
the allotted time the drug-containing media were removed and
replaced with fresh medium. The dishes were incubated under
the same conditions as those used for the controls. This
procedure was repeated except that BCNU was added first and
DTIC was added on day 0, 1, or 2 of exposure. The dishes

were incubated for 15 days and the colonies were then fixed
and stained. All colonies containing 50 cells or more were
counted.
The results showed that DTIC alone enhanced cell death
the longer it remained in contact with the cells. BCNU alone
had no effect at the concentration used.
The results for the dose schedule when DTIC was added on
day 0,followed by BCNU on day 2, showed a 60% decrease in
the observed surviving fraction of cells from the expected
surviving fraction of cells. This indicated that melanoma
cell death was enhanced and these results are in agreement
with the previous study conducted by Hill et al.
(unpublished).
The results for the dose schedule when BCNU was added on
day 0, followed by DTIC on day 1, showed a 66% decrease in
the observed surviving fraction of cells from the expected
surviving fraction of cells. But then, the decrease in
observed surviving fraction of cells from the expected
surviving fraction of cells rose from 66% to 26%. These
results were similar to the in vivo results seen in the study
conducted by Hill et al. (21). However, these in vivo
effects were not as dramatic as the effects seen when DTIC
was added first.
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I. INTRODUCTION

BCNU has many distinctive properties.
l). It is very unstable and will decompose 000emzymaticalIy
to yield vinyl carbooium ions, chloroethyl corbmoium ions and
organic chInroethyI iancyana1es. The chImroethyl corboniom
ion (or chIoroethyldiaznoium precursor) comes from the
nitr000 moiety of the parent compound (24).

Further

decomposition of this ion generates volatile products, such
as chInroethanol, acetaldehyde, vinyl chloride and
dichlnroetbane (ll). It is this ion that is considered to be
responsible for the alkylating effects with nucleic acids
that are observed in biological systems.
The chloroethyl iaocyunotem are derived from the N-3
moiety of the parent compound (24). The isucyonate causes
carbamoylatioo reactions with electron rich groups Ii-ka the
amino groups of proteins which generate stable urea
derivatives (7),
2). BCNO is very reactive and its chemical and biological
half-life is approximately 15 to 30 minutes (39).
3). It is lipid soluble and will readily cross the bloodbrain barrier. It is also easily transported into living
cells (46).
4). DCNU displays bone marrow toxicity in man (30).
5\. DCNU is equally effective, for a &.*veo concentration, on

*6

the plateau phase of growth and on cycling or actively
dividing cells (3).
6). The metabolic products of BCNU will bind to macromolecules by two mechanisms, alkylation and carbamoylation
(39).
The two prominent products of nitrosourea decomposition
are isocyanates and alkyldiazohydroxides. The latter
compounds are capable of alkylating nucleic acids and are
considered to be responsible for the antitumor effects
observed in biological systems (46).
DNA cross-links are usually produced by bifunctional
alkylating agents which cause bridge formations usually at
guanine N-7. Because this moiety of BCNU is only capable of
monofunctional alkylation, there was some question as to the
mechanism involved in the cytotoxicity of this agent.
However, studies have shown that the chloroethylnitrosoureas
are capable of cross-linking DNA, even though they have only
one alkylating functional group (26).
The cross-linking mechanism occurs in two steps.

It

starts with the chlorethylation of a nucleophilic site on one
of the DNA strands. Then the reaction continues with the
displacement of Cl by a nucleophilic site on the opposite
strand. This results in the formation of an ethyl bridge
between the two strands. Thus, BCNU can react with nucleic
acids causing structural changes (26).

2

There is still sore question as to the sites of reaction
of BCNU with DNA. Kramer et al. (28) identified two products
of the reaction of BCNU with polycytidylic acid. The first
product, 3-hydroxyethyl-CMP, is formed by the initial
chloroethylation of cytosine, followed by a displacement of
Cl- through a hydrolysis reaction.
The second product, 3,Y4-ethano-CMP, is also formed by
the initial chloroethylation of cytosine, but the
displacement of Cl in this case is caused by a second
alkylation of the cytosine moiety (28). It has become
evident that BCNU can chloroethylate many different DNA
sites. It is also possible that a second alkylation occurs
at another DNA site along with the displacement of Cl.
Some problems arise when trying to determine the sites
where these reactions are most likely to occur. In order for
an interstrand cross-link to be formed, the reaction sites
must be on opposite strands of DNA. But to complete the
cross-link, the two opposed reaction sites must be spanned by
a bridge which is composed of only two carbon atoms. This
limits the possible sites where cross-linking can occur,
unless the helix is severely distorted by the
chloroethylation reaction. The sites involved must be the
ones that are usually involved in hydrogen bonding between
the two bases. One pair of sites has been suggested by Kohn
(26) as involving a bridge that is formed across the guanine

3
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0-6 and the cytosine N-4. There has been some evidence to
support this hypothesis. Kramer et al. (28) found that the
cytosine N-4 position was involved in an intramolecular crosslinking when polycytidylic acid was reacted with BCNU. In
another study by Singer, et al. (48) it was found that ethylnitrosourea ethylated the guanine 0-6 of DNA.
In another study BCNU was shown to react with two
synthetic*polynucleotides. This compound is not considered a
typical bifunctional alkylating agent, but it does possess
some ability to alkylate polycytidylic and polyuridylic acid.
Ludlum et al. (33) attempted to determine the structural
modifications induced by BCNU. He isolated three nucleotide
derivatives, 3-(P-hydroxyethyl)-CMP, 3,0-ethano-CHP, and
7-(p-hydroxyethyl)-GMP. All of these altered bases were
created by the generation of a two-carbon fragment which is
found in the chloroethyl carbonium ion. This two-carbon unit
is free to interact with the nucleotides and causes the
changes observed in this study.
There are, however, other studies that do not show any
direct evidence which supports the findings mentioned in the
preceding studies. The previous evidence suggested that the
alkylation mechanism, and not the carbamoylation mechanism,
caused by BCNU is the mechanism that will inhibit DNA
synthesis in certain cases. Wheeler et al. (53) found that
using BCNU concentrations of 2.5 x 10-3 H caused a decrease

in DNA synthesis by intact L1210 cells and also a decrease in
the activity of the DNA polymerase enzyme, nucleotidyltransferase. However, this concentration of BCNU did not
change the DNA primer activity. Yet a concentration of 1 x

10

3

M of BCNU inhibited the synthesis of DNA, but without a

decrease in the DNA nucleotidyltransferase activity.
Therefore, the deactivation of this enzyme is probably not
the cause. of decreased DNA synthesis. During this study, it
became evident that when a substituent was present on the N-3
of the nitrosourea, the activity of the nitrosourea was
increased. Thus, the newly generated isocyanate (derived
from the decomposition of the parent compound) could possibly
be involved in the inhibitory activity of DNA synthesis.
This is consistent with the findings that BCNU and 2chloroethyl isocyanate were equal in inhibitory activity in
this study. Also, it appeared that the inhibition of the
incorporation of 14 C from deoxythymidine-5'triphosphate- 2_14c
into nucleic acids by the enzyme preparations from L1210
ascites cells was caused by the 2-chloroethyl isocyanate, and
not the alkylating moiety that is generated when the BCNU
molecule is cleaved. Thus, it was concluded that the
carbamoylation of the polymerase enzyme, and not its
alkylation, is responsible for the inhibitory activity of
BCNU.
The isocyan:!tes, which are very reactive and have strong
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carbamoylating activity, are not considered to playa crucial

role in the antineoplastic effects of the parent
nitrosoureas. However, the activity of the isocynates is of
significance because they can alter proteins and inhibit DNA
repair processes. This repair mechanism could be responsible
for preventing cells from being killed by oncolytic compounds
which cause DNA damage. There has been some evidence to
support this hypothesis.
Kann et al. (23) showed that 2-chloroethyl isocyanate
(CIS) interfered with repair of DNA damaged by x-rays or
ultraviolet radiation. It was thought that this effect was
caused by the inhibition of the enzymes that bind to nucleic
acids. The mechanism assumed to be responsible for this
effect is thought to involve the loss of a positively charged
lysine amino group. This could interfere with the ability of
a protein to bind to a negatively charged nucleic acid.
carbamoylation reaction is believed to cause this loss of the
lysine amino group. However, there is no direct evidence
demonstrating that the repair enzymes are inhibited. It is
hypothesized that another mechanism could be involved such as
the modification of nonenzymatic nuclear proteins.
Fornace et al. (15) continued to try to prove that CIS
does interfere with repair mechanisms. It was found that CIS
did not affect the endonuclease step of repair synthesis due
to UV-induced strand breaks, but it did prevent the rejoinirg

of strand breaks. This indicated that the ligase step in DNA
repair was inhibited. CIS is unique because it is the only
known compound that can cause this effect on the ligase step
of DNA repair.
In another study Wheeler et al. (53) showed that CIS was
responsible for the decreased activity of DNA nucleotidyltransferase when crude enzyme preparations from L1210 ascites
cells were incubated with concentrations of 2.5 x 10-3 M of
BCNU. Thus, under some conditions BCNU and its decomposition
product, CIS, can cause a decrease in the DNA nucleotidyltransferase system. But the deactivation of this enzyme is
probably not responsible for a decrease in DNA synthesis in
vivo.
Baril et al. (2) found that CIS affected an enzyme
involved in the DNA replication process and not the repair
process. CIS inhibited only one of the two nonmitochondrial
DNA polymerases, DNA Polymerase II, that was purified from
rat liver and hepatoma cells. Although the function of this
enzyme is unclear, it is thought that it plays a role in the
DNA replication of tissues. The activity of this enzyme is
low in nonproliferating tissues and increases as the growth
rate of the tissues increase. The DNA polymerase I was not
inhibited by CIS. This enzyme does not respond when cells
are proliferating and is thought to be involved with the
repair processes. The mechanism of action is still an

untested assumption, but it is believed that the observed
effects are caused by the carbamoylation of a critical
cysteine moiety located at or near the site of the polymerase
enzyme. This is thought to be true because the isocyanates
are known to form stable carbamoyl derivatives with many
amino acids in proteins. This mechanism is probably not the
only mechanism that causes the enzyme inhibition because it
was found,•in this study, that a carbamoyl derivative of
cysteine can be unstable at the pH used for the enzyme assay.
Many other effects observed in biological systems could
be due to the carbamoylating effects of BCNU. Kann et al.
(24) found that CIS was responsible for the inhibition of RNA
maturation of ribosomal precursor RNA and with nucleoplasmic
messenger precursor RNA. During the maturation process the
high—molecular weight RNA chains are shortened. The 45 S and
32 S chains in the nucleolus were prevented from being
shortened by cleavage and degradation. Thus, the inhibition
caused by BCNU resulted in the persistance of long RNA
molecules. In addition these long chains were prevented from
leaving the nucleoplasm.
This observed effect is not the one that is hypothesized
as the mechanism responsible for the therapeutic antitumor
effects of BCNU. The structural activity of some of the
nitrosoureas requires that the N-3 nitrogen of the urea
moiety be substituted. The isocyanates of BCNU and
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l-( chloroethyl)-3-cyclohexyl- nitrosourea (CCNU) were
found to be more effective than the parent compounds.
Because of this observed effect, it is thought that the
metabolites are the ones responsible for the inhibition of
RNA maturation.

If the N-3 nitrogen substituent is necessary

for the metabolite to cause the effects on RNA, then the
isoccyanate product of CCNU would be inactive. This is not
the case.' This decomposition product is very active against
neoplasms. Thus, it was concluded that RNA maturation
inhibition and/or other effects caused by the isocyanates are
not the effects responsible for antineoplastic activity. It
is more likely that these effects cause the toxic side
effects associated with the use of these drugs (24).
Another effect of the carbamoylating activity of BCNU is
observed during de novo purine biosynthesis.

It affects the

biosynthesis process in several ways. First, it increases
the rate of incorporation of formate- 14C into purines.

BCNU

is thought to affect a certain reaction which involves the
insertion of either the C-2 or C-8 position of the purine
ring. Second, it inhibits the contribution of histidine as a
donor to the 1-carbon endogenous pool of FR4 coenzyme
derivatives which are involved in the metabolism of
tetrahydrofolic acid derivatives.

The metabolism of these

coenzymes are part of the de novo purine nucleotide synthesis
pathway. It is thus speculated that a selective

A

carbamoylation mechanism of these enzymes is responsible for
the effects observed in this study (Groth et al. 19).
In summary, there are at least two theories that could
explain the mechanisms of action of BCNU.
1). BCNU is thought to possess alkylating capabilities due to
the creation of a carbonium ion which can react with nucleic
acids and DNA.
2). BCNU tan cause carbamoylation reactions. This effect is
caused by the isocyanates which will react with electron rich
groups found in the amino acids of proteins.

The characteristics of DTIC are:
1). It is very unstable and is decomposed via two mechanisms,
photodecomposition and microsomal metabolism (8)(17)(31)(44).
2). The metabolites, and not the DTIC, are considered to be
pharmacologically active (17)(31)(32)(44).
3). DTIC (like BCNU) appears to be non—cell cycle stage
specific. Wilkoff et al. (54) proposed a first order
kinetics model for the killing of L1210 cells by DTIC. Thus
it was suggested that the percentage of cells killed is
unrelated to the number of viable cells present.
DTIC is probably inactive in biological systems and
therefore must be activated in order to produce the anti—
tumor properties that have been clinically demonstrated.
There are two known metabolic pathways that create bio-
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logically active metabolites (I7)/51l(32)(44)_
The first patbway 10 induced by long-wave ultraviolet
light which converts DIIC to 4-diazoimidamole-5-corboramide
(DZC). This metabolite is u very reactive electrophlIe and
highly cytntoxic. Dimethylamiue, a biologically noncytotoxic compound is also created during this step of the
reaction. The DZC spontaneously cycIizes to 2azahypozaiithioe (aza-8x). This metabolite is not as toxic as
its predecessor. Yamamoto et al. (55) showed that DZC was
I000 times more potent than aza-8z as an inhibitor of E. coIi
cell growth. This activity of oza-Bx against E. cnli was
counteracted by hyynxauthine. Consequently it is doubtful
whether aza-hz possesses any biological activity at all (8).
It is hypothesized that the metabolite DZC is responsible
for the inhibitory effects on DNA biosynthesis (44)(51) but
not on RNA or protein synthesis (55). Yamamoto (55) found
that low concentrations of DZC ranging from l Jug/ml to 10
,ug/ml inhibited the growth of E. coIi cells without causing
the cells to lyae. This effect was also seen in resting
cells, as well as in actively dividing cells. When cyateioe
was added to cultures incubated with DZC, the inhibition of
cell growth was prevented.
Saunders et el. (43)/44) showed inhibited cell growth of
cultures of Bacillus aublilia when incubated with DZC. When
hiQh levels of reduced glntathione were added to the
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cultures the DNA inhibition caused by DZC was reversed. This
would be expected, since the diazo compound couples very
easily with sulfhydryl groups and also with reactive sites on
nucleic acids. Because of this it has been suggested that
this action may have something to do with the pharmacological
action of DTIC. Therefore, the addition of nontoxic
sulfhydryl compounds such as glutathione and cysteine would
bind to the DZC and reverse the inhibition of cell growth
caused by incubating the cells with DTIC in the presence of
light.
Though this metabolite has a strong affinity for
nucleophilic groups there is some question as to its ability
to be very reactive since it is a dipolar molecule. This
could hinder its capability to be transported through the
cell membrane and enter the cell. But Loo et al. (31)
postulated that if DZC was produced rapidly enough some of it
could find a way into the cells which would enable it to
interact with the intracellular molecules such as DNA and
RNA. Saunders et al. (43) showed in experiments with DTIC-2C that the diazo compound does indeed enter the cells.
Though DZC has been postulated to be the pharmacologically active form of DTIC (20)(44)(50), Mizuno et al.
(37) found contradictory results. Radioactive DTIC was
allowed to photodecompose to DZC in the presence of RNA and
DNA. These macromolecules showed virtually no radioactivity.
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Though the diazo compounds are known to readily couple with
many reactive groups it appeared unlikely that the alkylation
of nucleic acids occured during this study with S180 tissue.
To further support this hypothesis, Mizuno et at. (37) found
that in the presence of light, DTIC gave a negative response
to a test used for the detection of alkylating agents.
There is another means of activating DTIC via microsomal
metabolism in vivo. 5-(3-methyl-l-triazeno)imidazole-4carboxamide (MIC) and formaldehyde are formed from DTIC by
oxidative N-demethylation (49). In this step the DTIC loses
an N-methyl group ultimately as CO2. MIC then tautomerizes
to 5-(3 methyl-2-triazeno)imidazole-4-carboxamide (iso-MIC).
This compound spontaneously cleaves to generate 4(5)diazomidazole-5(4)-carboxamide (AIC), diazomethane (a
methylating intermediate) and a methyl carbonium or diazonium
ion (50). It is hypothesized that the diazomethane ion
and/or the carbonium ion are the agents responsible for the
observed methylation of nucleic acids and proteins
(31)(36)(37).
Even though light is absent in this reaction pathway,
some DZC is generated from DTIC at sufficiently reduced
rates. This permits the reactions of the microsomal pathway
to take place (17)(31).
MIC is thought to be involved in the methylation of
nucleic acids. Mizuno et al. (37) found that DTIC

selectively inhibited DNA synthesis in Sarcoma 180 slices.
When the metabolite MIC was tested with the reagent
4-(4-nitrobenzyl) pyridine, it produced a strong positive
reaction for the detection of alkylating substances.
In a study conducted by Skibba et al. (51) DTIC, or an
active metabolite (MIC), selectively inhibited the
incorporation of labeled thymidine into DNA. It did not
effect the incorporation of precursors into RNA or proteins.
MIC also prevented DNA synthesis in the thymus, liver, spleen
and small intestine in normal proliferating rat tissues.
However, the study of DTIC on nucleic acid synthesis has
shown variable results. In a study by Shirakawa, (47) DTIC
was reported to affect RNA and protein biosynthesis more than
DNA biosynthesis in L1210 cells. Contradictory results were
also reported by Pittilo (41). In this study an analog of
DTIC, (methyl 5 (or 4)-(3,3=dimethyl-l-triazeno)imidazole-4
(or 5)-carboxylate was reported to inhibit the growth of grampositive, gram-negative bacteria, yeasts, filamentous fungi
and algae in vitro. A concentration of 1.0 pg/m1 was
sufficient to markedly inhibit the RNA and protein synthesis
processes in E. coli. A stronger concentration of 5.0 pg/m1
totally inhibited these same processes. However, DNA
synthesis was unaffected. Cysteine completely reversed the
inhibition of this compound for E. coli suggesting that a
competitive reversal mechanism was involved.
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Further studies by Mizuno et al. (36) found that
concentrations of MIC. greater than 1 x 10-3M inhibited the
growth of mouse fibroblast tissue culture cells. In this
3
same study, MIC prevented RNA from incorporating H-uridine,
and prevented DNA from incorporating 3H-thymidine. There was
some evidence that MIC was involved in de novo purine
synthesis. When L cells were incubated with 3H-MIC, three
purine bases incorporated the radioactive molecule. They
were adenine, guanine and 7-methyl guanine. To determine if
this effect, caused by MIC on nucleic acid synthesis, was a
result of impaired template activity, RNA and DNA polymerase
activities were studied.

DNA incubated with MIC showed

reduced template activity with RNA polymerase but not with
DNA polymerase. However, when L cells were incubated with

MIC, both DNA and RNA synthesis was inhibited. The
conclusion of this study was that MIC-treated cells did
impair DNA synthesis but the cause could not be attributed to
diminished template activity. It seemed that other factors
were involved. It was concluded that the methylation caused
the initial error. This then led to additional inactivation
which was caused by the production of nonfunctional RNA or
proteins.
Other studies support the existence of DNA damage caused
by methylation. Strauss et al. (52) reported that methylated
DNA caused single strand breaks either directly or by

15

enzymatic action. Consequently it is possible that the
lesions created by the repair of the breaks might be of such
magnitude as to prevent the altered DNA from acting as a
template for RNA or DNA synthesis. This study also showed
that the methylated DNA lost its ability to participate in
bacterial transformation.
During another study by Mamet—Bratley (34), it was shown
that there'could be enough damage caused by methylation to
interfere with the biological function of DNA. The altered
molecule was shown to reduce the normal template activity for
RNA synthesis. There are four postulated theories to explain
the effects caused by alkylation on RNA synthesis.
1). The elongation of the chain is slowed down due to steric
obstacles that are created by the incorporation of the alkyl
groups into the DNA template.
2). The termination of the chain elongation is prematurely
stopped.
3). There is an inhibition of the normal enzyme binding
process.
4). The initiation of the chain synthesis is prevented.
There is a question as to whether the methylation
of RNA or DNA by DTIC can be responsible for the inhibition
on DNA synthesis. Roberts et al. (42) showed that mammalian
cells were capable of removing alkyl groups from DNA and can
carry out a repair synthesis of DNA. For example, the
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lesions caused by an alkylating agent such as mustard gas in
a DNA molecule could be repaired. The repair mechanism
begins by the removal of the alkylated lesions. The cell
then replaces the excised portion of the DNA molecule using
the remaining undamaged strand of DNA as a template. This
repair synthesis is very different from normal semiconservative replication. There are nucleolylic enzymes that
recognize elkylation damage and these enzymes are different
from enzymes involved in recognizing UV damage (52).

This

mechanism, which repairs lesions in the DNA, could account
for the resistance of some cells to the cytotoxic effects of
alkylating agents.
The microsomal metabolism of DTIC has been shown to cause
other effects. In a study by Larson et al. (29) DTIC was
able to completely inhibit the breakdown of the low K m form
of c-AMP phosphodiesterase in the supernatant of rat livers.It is well known that high concentrations of intracellular
c-AIP can inhibit cell growth. This might he a significant
contribution to the pharmacological control of tumor-cell
growth since DTIC alters c-AMP levels.
Culver et al. (13) found that DTIC inhibited neuroblastoma cell division. It also increased the activity of
three enzymes that are involved in neurotransmitter
metabolism. They were tyrosine hydroxylase, choline
acelyltransferase and acetylcholinesterase. The cells became
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enlarged clue to the elevated protein content. DTIC did not
affect the intracellular c-AMP levels or the c-AMP
phosphodiesterase activity.
Gerulath et al. (16) observed a broad shoulder thresholdtype survival curve when chinese hamster ovary cells were
incubated with DTIC. This survival curve existed in both
light and dark conditions. This suggested that sublethal
damage occurs via both metabolic pathways. There is also the
possibility that a threshold dose exist below which there
seems to be no cell death. This effect could also be
explained by the existence of a repair process by which some
of the cells are capable of recovering from the sublethal
damage. The shoulder might also be caused by pharmacological
mechanisms such as membrane exclusion of the drug or
metabolic activation of the drug.
Another interesting characteristic of DTIC is its ability
to mediate immunogenic changes of experimental tumors. In a
study by Nicolin et al. (38) 5178 leukemia cells became more
immunogenic when treated with DTIC. When these treated
leukemia cells were injected into otherwise susceptible
syngeneic hosts, their survival rate was prolonged, sometimes
indefinitely. It was suspected that the DTIC treatments
induced the appearence of additional new target antigens on
the tumor cells rather than increase pre-existent
antigenicity in the tumor cells. Similar antigenic changes
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were observed in two other leukemia cell lines, 1.1210 Cr and
L1210 Ha by Bonmassar et al. (6). However, the mechanism
responsible for the new antigen's appearance is not yet
clear. Several mechanisms for its appearance have been .
hypothesized.
1). The DTIC activates a latent virus which causes the
appearance of new virus-coded transplantation membrane
antigen(s)•(14).
2). The DTIC caused somatic mutations which affect membrane
antigens due to its alkylating properties or its ability to
bind to nucleic acids. It was postulated by Giampietri et
al. (18) that these mutations were caused by one of the above
mentioned properties of DTIC. This resulted in the
overgrowth of highly immunogenic clones. This then led to
the appearance of sublines that carried strong transplantation antigens that could be recognized by hosts-that were
histocompatible with the parental cell line.

These findings

are significant since cancer immunotherapy is based on the
difference between normal cell antigens and tumor cell
antigens.

In summary, there are at least three theories that could
explain the mechanism of action of DTIC (9)(13).
1). DTIC has been shown to prevent the synthesis of DNA.
This could be due to the sterio-chemical properties of the
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drug which somehow causes it to act as a purine analog and
thus causes it to interfere with de novo purine synthesis.
2). The metabolism of this drug ultimatly creates a carbonium
or diazomethane radical ion which is thought to possess
alkylating activity.
3). DTIC or its metabolites are highly reactive to sulfhydryl
(S-H) groups. It was shown in many studies that the addition
of compounds that contain numerous S-H groups caused
competitive reversal of DNA synthesis inhibition or cell
growth inhibition.
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II. Materials and Methods

CHEMICALS
DTIC (NSC-45388) was obtained from Dome Laboratories,
West Haven, Conn. It was dissolved in a 1% citric acid and
0.52 mannitol solution. The initial concentration was 10
mg/ml of DTIC to solution. This solution was sterilized by
filtration. with a Millipore membrane of 0.22 pm. It was kept
on ice and protected from the light. The final concentration
used per dish was 1.0 mg/ml.
BCNU (NSC-409962) was obtained from The National Cancer
Institute.

It was dissolved at 1 mg/ml in distilled

deionized water and sterilized by the same method as the
DTIC. This solution was also kept on ice and protected from
the light. The final concentration used per dish was 1.0
pg/ml.
A stock solution of 1% citric acid and 0.5% mannitol was
made and sterilized by the same method as DTIC. This was
used as one of the controls.
CULTURES
The mouse melanoma cells have been cultured in the
laboratory since 1974. They were originally obtained from a
B16 tumor that was growing in a C57BL/6 female mouse.
These B16C14 melanoma cells were grown on Dulbeccos Modified
Eagle Medium (GIBCO) with 5.0% fetal bovine calf serum
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(GIBCO) and 0.1% penicillin streptomycin (GIBCO). The medium
(DME5) was sterilized by filtration using a Millipore
membrane of 0.22 um. The cells were incubated on P60 dishes
(60 mm. diameter) at 37°C and in humidified conditions (5% CO2
and 100% humidity).
PROCEDURES
The cultures were allowed to grow on P100 dishes
(100 mm. diameter) until confluent. The medium was removed
and trypsin with EDTA (lx) (GIBCO) was used to detach the
cells growing on the bottom of the dish. The cell
concentration of the resulting suspension was estimated using
a haemocytometer. Two concentrations of cells were made by
suspending the cells in the DME5 medium. The final
concentrations of cells per dish were 200 cells per dish and
500 cells per dish. The cells were inoculated on to P35 (35
mm. diameter) dishes.

Two replicates of each dish were

made. Each dish contained a final volume of 2 ml of the
seeded medium. The dishes were incubated in the dark for
approximately one hour to allow the cells to settle. During
this time the drug(s) solutions were prepared, sterilized,
kept on ice and protected from the light. The dishes were
then removed from the incubator and the drug(s) were added in
a dark laminar vertical air flow hood.
The dose schedule appears in TABLE I.
The dishes were incubated in the dark to prevent

22

photoactivation. On day 2, 3, or 4 according to the
schedule, the dishes were removed from the incubator and the
medium was removed. Each dish was rinsed two times with 1%
calcium-magnesium free phosphate buffer saline (CALF-PBS).
This solution was prepared from a stock solution and was
sterilized using a Sybron/Nalge type S filter unit.
Fresh medium was added and the dishes were allowed to
incubate in the dark for a total of 15 days. At the end of
the 15 days the dishes were rinsed with a saline solution
(0.9g/100ml distilled deionized water). The cells were fixed
and stained with a crystal violet solution containing 10%
formalin. The dishes were scanned macroscopically for
colonies that contained 50 or more cells. These colonies
were marked and counted.
CALCULATIONS
The plating efficiencies for Group I, II, and III were
calculated by dividing the average of the number of surviving
colonies from the two replicated dishes, divided by the
number of original seeded cells per dish. In all
calculations, only the 200 cells per dish results were used
because the 500 cells per dish tended to be confluent and
hence impossible to score. For example, when no drug was
added and the medium was changed on day 2, the number of
colonies that were found on each of the two dishes were 65
and 66. (Refer to TABLE II). The average of this is 65.5.
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This number was divided by 200 (original number of cells per
dish) to yield a plating efficiency of 0.3275. (Refer to
TABLE III and IV). The plating efficiencies for the control
group I were averaged. This average is used in later
calculations to derive the observed surviving fraction of
cells when the drug(s) are added individually (Group II).
The observed surviving fraction of cells for group II
was calculated by dividing each plating efficiency from group
II for day 2, 3, or 4 of medium exchange, by the plating
efficiency average of the control group I (Refer to Table V).
The observed surviving fraction of cells from Group III was
also obtained in like manner. For example, when DTIC and BCNU
were added on day 0 and DME5 was changed on day 2, the
plating efficiency was 0.3375. This number was divided by
0.342 (control average) to yield 0.987 (Refer to Table VI).
The expected surviving fraction of cells from Group III
was obtained by multiplying the observed surviving fraction
of DTIC treated cells by the corresponding expected surviving
fraction of BCNU treated cells from Group III. For example,
when DTIC was added on day 0 and the medium was changed on
day 2, the surviving fraction, 0.811, was multiplied by the
surviving fraction, 0.914, which was obtained when BCNU was
added on day 0 and the medium was changed on day 2. This
calculation yielded the expected surviving fraction, 0.714,
DTIC and BCNU added on day 0 and the medium changed on dad 2
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(Refer to Table VI).
The percent increase of decrease of the observed
surviving fraction of cells from the expected surviving
fraction of cells was calculated by dividing the former
number by the latter number. This result was subtracted from
one and multiplied by one hundred to yield the final number
as it appears in the last column of Table VI. This was done
for each set of drugs in Group III. For example, when DTIC
and BCNU were added on day 0, and the medium was changed on
day 2, the observed surviving fraction 0.987, was divided by
the expected surviving fraction, 0.741, to yield a 33%
increase in the observed surviving fraction from the expected
surviving fraction.

(Refer to Table VI).
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III.

RESULTS AND DISCUSSION

Two control groups were established during this
experiment, dishes with no drugs and dishes with only the
citric acid and mannitol solution. This latter control was
used to ensure that killing was caused by the DTIC and not
the solution in which it was dissolved. The first control
group, in Which no drug or solution was added to the seeded
medium, produced a plating efficiency average of 0.3350. The
second control group, in which only the citric acid and
mannitol solution was added produced a plating efficiency
average of 0.3480. There is no significant difference in
these two averages, indicating that the citric acid and
mannitol solution did not cause cell death. The average of
these two plating efficiencies was 0.342.
As expected, the DTIC when added alone increased cell
mortality. This was shown by the continuous decrease in
observed surviving fraction of cells, which started at 0.811
and dropped to. 0.139. The longer the drug was left in
contact with the cell population, the greater the percentage
of cells killed. This is in agreement with Wilkoff's et al.
(54) first order kinetics model that was demonstrated for
DTIC treated L1210 cells. The rate of viable cell reduction
was not dependent on the number of living cells in the
population for a given drug concentration and Oven dose
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period.
The results also indicated that this particular cell
line, B16CL4, still retained a means to enzymatically
activate the DTIC in vitro. Thus Miller's et al. (35)
hypothesis concerning the lack of enzymes necessary to
activate the DTIC in older mammalian cell cultures was not
valid for this culture line of mouse melanoma cells. Thus, a
S9-mixture'of microsomal enzymes from a liver homogenate of
mice treated with Aroclor 1254 as described by Ames et al.
(1) was not needed.
Many studies have shown that DTIC and/or its
metabolites, DZC or MIC, inhibit the growth of bacteria or
mammalian cell cultures. (36)(37)(41)(44)(51)(55)

It is

assumed in this study that the enzymatic metabolic pathway
was the one responsible for the activation of the drug(s).
This -was concluded because the drugs and treated cultures
were protected from photodecomposition.
The mechanism of action of this drug has not yet been
elucidated. Some hypotheses suggest that DTIC inhibits DNA
synthesis (36)(37)(51), RNA synthesis (35)(36)(41)(47),
or protein biosynthesis (41)(47). The metabolically active
metabolite, MIC, has been shown to impair template activity
(52), either by interfering with the RNA polymerase enzymes
(36) or the DNA polymerase enzymes. The template activity
has also been shown to be affected by the methylation of DNA
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single strands, which cause breaks. Although the breaks are
repaired, the numerous lesions that are created could
interfere with the template activity of DNA.
The plating efficiencies obtained from the experimental
addition of BCNU added alone did not significantly differ
from one another.

Differences observed are probably due to

experimental variation.
The purpose of this study was to establish a synergistic
dose schedule for DTIC and BCNU. It has been shown by Hill
et al. (21) that an enhancement dose schedule does exist when
DTIC is administered to female BALB/C x DBA/2 Fl mice bearing
Harding-Passey mouse melanoma cells on day 0 and
1-(2-chloroethyl)-3-(4-methylcyclo-hexyl)-1-nitrosourea
(MeCCNU) is administered on day 1. When this dose schedule
was administered, 90% of the mice were cured. The
enhancement of the survival of the mice was not as great when
the order of the drugs was reversed. MeCCNU, like BCNU,
produces an alkylating moiety and a carbamoylating moiety.
These two nitrosoureas posssess similar structures and could
have similar mechanisms of action. In another study by

Hill

et al. (unpublished) enhancement was also observed when DTIC
was administered to mice, bearing B16 mouse melanoma cells,
on day 0 followed by the administration of BCNU on day 2.
In the present study, the results obtained when DTIC and
BCNU were added on day 0, showed a 32% increase of the

•.
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observed surviving fraction of cells from the expected
surviving fraction of cells. This dose schedule did not
produce any killing enhancement. When DTIC was added on day
0 and BCNU was added on day 1, there was a 43% increase of
observed surviving fraction of cells from the expected
surviving fraction of cells. This dose schedule also di,d not
produce an enhancement of cell death. Significant results
were obtained however, when DTIC was added on day 0 and BCNU
was added 2 days later. This dose schedule produced a 60%
decrease in the observed surviving fraction from the expected
surviving fraction. Cell death was enhanced when the drugs
were added in this manner. This corresponds closely with the
results obtained from the two previously mentioned reports by
Hill et al. (21) (unpublished).
These enhanced effects could be caused by the
metabolite HIC, which is thought to cause the initial damage
to the DNA molecule. The alkylation mechanism could have
caused strand breaks in the molecule, thus interfering with
DNA or RNA template activity. BCNU then produced a
carbamoylation reaction which caused the inhibition of the
repair enzymes. A similar effect was observed by Kann et al.
(23). In this study CIS interfered with the repair of DNA,
which was damaged by an alkylating mechanism caused by x—
rays. Fornace et al. (15) found that CIS prevented the
rejoining of strand breaks by interfering with the ligase
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step of DNA repair. These breaks were caused by exposing the
cells to x-rays.
In another study by Shirakawa et al. (47) DTIC produced
an effect on the G

2

period in the mitotic cycle. Because of

its alkylating abilities, DTIC caused the G2 phase to be
prolonged. This prolongation was responsible for the adverse
affect on RNA and protein biosynthesis more than on DNA
synthesis; Thus, the content of DNA increased in each cell
because of the delay during the G2 phase. It is during this
time that the DNA strands have doubled, but division has not
yet taken place. During the same study BCNU was show to
produce a prolongation of the S phase of the mitotic cycle.
This interfered with DNA synthesis.

There was a strong

correlation between the delayed S phase and cell death. Both
of these drugs have been shown to interfere with different
stages of the mitotic cell cyle. Enhanted cellular
destruction could have resulted because each of the drugs
causes its effects at different times during the growth of
proliferating cells.
The results obtained from the BCNU added first trial
were expected. When BCNU and DTIC were added on day 0, (in
the BCNU added-first trial) the same result, a 337 increase
in the surviving fraction, occurred as in the DTIC addedfirst trial. This was expected since both drugs were added
at the same time in both trials.

This increase could be

explained by several speculations. Either the drugs were
interfering with each other or there was experimental
variation in the controls. There was a significant decrease,
66%, in the observed surviving fraction from the expected
surviving fraction when DTIC was added 1 day after BCNU. But
when DTIC was added 2 days after BCNU, the observed surviving
fraction rose to 26% of the expected surviving fraction. It
is possible that the DTIC may not have been activated during
this dose schedule. There might have been more enhancement
if a S9-microsomal mixture had ben included in the
experiments. Also, the drug mechanisms may have interfered
with each other to cause the observed effects.
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TABLE I.

DOSE SCHEDULE

DAY OF ADDITION OF DRUG(S) OR SOLUTIONS

DTIC

Citric acid
mannitol solution

BCNU

DME5

2

0
0

0

2
2
2
2

0
0

0

0
0
1

-

1
-

3
3

-

1
0
1

0
0
-

3
3
3
3

0

2

0

2

0
0

2
0
2
(-)

nothing added
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4
4
4
4
4
4
4

Table II.

INITIAL RESULTS

DAY OF ADDITION OF DRUG(S)
OR SOLUTIONS

DTIC

CIRTIC

BCNU

DME5

ACID/
MANNITOL

0
0

0
0

0
0
-

-

1

0
1

NUMBER OF COLONIES
PER DISH

200 CELLS
/DISH

500 CELLS
/DISH

2
2
2
2
2

65
75
57
63
69

66
60
54
62
67

65.5
67.5
55.5
62.5
68.0

C
91
99
72
C

C
104
102
C
C

3
3
3
3
3
3
3

C
19
21
21
79
74
80

C
19
8
23
72
74
71

19.0
14.5
22.0
75.5
74.0
75.5

C
57
34
52
C
C
C

C
67
49
54
C
C
C

C
3
14
96
C
C
C

C
12
20
99
C
C
C

65
4
4

(-) nothing added
(C) confluent dish

AVG

9
37
61
67
67

72

68.5

6
10
37
62

3.5

9.5
37.0
61.5

65

67.0
66.0

AVG

97.5
100

62.0
41.5
53.0

7.5
17.0
97.5

TABLE III.

PLATING EFFICIENCIES AND
PLATING EFFICIENCY AVERAGES
OF CONTROLS

CONTROLS GROUP I

DRUG

DAY OF
ADDITION
OF DRUG

DAY OF
ADDITION
OF FRESH
MEDIUM

PLATING
EFFICIENCY

PLATING
EFFICIENCY
AVERAGE

none
none
none

-

2
3
4

0.3275
C
0.3425

0.3350

citric
acid/
mannitol

0
0
0

2
3
4

0.3400
0.3700
0.3350

0.3480

average of both control groups is 0.3420

(C) confluent dish

:55

TABLE IV.
PLATING EFFICIENCIES OF DRUG TREATED CELLS
DRUGS ADDED ALONE GROUP II
DRUG

DAY OF
ADDITION
OF DRUG

DAY OF
ADDITION
OF FRESH
MEDIUM

PLATING
EFFICIENCY

DTIC
DTIC
DTIC

0
0
0

2
3
4

0.2775
0.0725
0.0475

BCNU
BCNU
BCNU

0
0
0

2
3
4

0.3125
0.3775
0.3075

DRUGS ADDED TOGETHER GROUP III
DTIC ADDED FIRST
DRUG

DTIC
DTIC
DTIC

DAY OF
ADDITION
OF DRUG
0
0
0

DRUG

BCNU
BCNU
BCNU

DAY OF
PLATING
DAY OF
ADDITION ADDITION EFFICIENCY
OF DRUG
OF DME5
0
1
2

2
3
4

0.3375
0.0950
0.0175

BCNU ADDED FIRST
DRUG

DAY OF
ADDITION
OF DRUG

DRUG

BCNU
BCNU
BCNU

0
0
0

DTIC
DTIC
DTIC

DAY OF
DAY OF
PLATING
ADDITION ADDITION EFFICIENCY
OF DRUG
OF DME5
0
1
2

2
3
4

3';

0.3375
0.1100
0.1850

TABLE V.

OBSERVED SURVIVING FRACTION
OF DRUG(S) ADDED ALONE

DRUGS ADDED ALONE GROUP II
DRUG

DAY OF
ADDITION
OF DRUG

DAY OF
ADDITION
OF DRUG

OBSERVED
SURVIVING
FRACTION

DTIC
DTIC
DTIC

0
0
0

2
3
4

0.811
0.212
0.139

BCNU
BCNU
BCNU

0
0
0

2
3
4

0.914
1.104
0.899

;7

TABLE VI.

OBSERVED AND EXPECTED SURVIVING FRACTION OF CELLS
AND PRECENT INCREASE OR DECREASE OF SURVIVING FRACTION
OF CELLS FOR DRUGS ADDED TOGETHER

DRUGS ADDED TOGETHER GROUP III

DTIC ADDED ON DAY 0

DRUG

BCNU
BCNU
BCNU

DAY OF
DAY OF
OBSERVED
EXPECTED
PERCENT
ADDITION ADDITION SURVIVING SURVIVING INCREASE/
OF DRUG
OF FRESH
FRACTION
FRACTION
DECREASE
MEDIUM
SURVIVING
FRACTION
0
1
2

2
3
4

0.987
0.278
0.051

0.741
0.194
0.127

33% >
43% >
60% <

BCNU ADDED ON DAY 0

DRUG

DTIC
DTIC
DTIC

DAY OF
DAY OF
OBSERVED
PERCENT
EXPECTED
ADDITION ADDITION SURVIVING SURVIVING INCREASE/
OF DRUG
OF FRESH
FRACTION
FRACTION
DECREASE
MEDIUM
SURVIVING
FRACTION
0
1
2

2
3
4

0.987
0.322
0.541

0.741
0.895
0.729

33% >
66% <
26% <

(>) Increase in observed surviving fraction from expected
(<) Decrease in observed surviving fraction from expected
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